No experience
Employment Type:
Full time
Job Category:
Information Services
Asset Management SMA Manager for Korea
Biogen | Cambridge, Massachusetts
Tell Us More About Your Job Preferences
By telling us what you think of this job, we can help find jobs that match your interests. If you want to see more jobs like this, click on the smiley face. Or if this job isn't what you are looking for, click the frowny face. Learn More...

Follow This Company

Job Description

External Posting TitleAsset Management SMA Manager for Korea
Job DescriptionEvery day at Biogen, we work to break new ground with science that makes a difference in the lives of patients around the world. Hiring the right talent and nurturing employees across all aspects of our business allows us to innovate, execute and achieve outstanding results. That's why people are Biogen's strategy for success. We currently have an incredible opportunity for an individual motivated to work for a company that cares deeply and works fearlessly for the lives of patients globally.

Biogen's Global Therapeutic Operations Accelerated Leadership Program is a two-year program designed to attract talented and highly motivated MBA graduates who want to make a meaningful impact early in their careers, and who appreciate our deep focus on and commitment to our patients, which is core to our company culture. The Manager, Asset Management SMA will have the opportunity to work alongside some of the most talented professionals in the industry amidst an unprecedented launch of a breakthrough new therapy for one of the world's most devastating rare diseases, Spinal Muscular Atrophy, which is the most common genetic case of death amongst infants. The Asset Management Manager, SMA for Korea will apply their knowledge and learnings to help drive Biogen's global expansion efforts by helping to lead the launch of this therapy in new geographies for Biogen across our APAC region.

While in the 24-month program, the Manager, Asset Management SMA can expect to gain:

• Expertise in critical functional areas such as Value & Access, Global Asset Management and Strategy, US Therapeutic Operations, Global Marketing and Business Development.

• Global, cross-functional project management experience

• Experience working across functions and global geographies

• Exposure to managing within a matrix environment

• Experience designing solutions for outcome measurement

• Mentoring and coaching from senior management and peers

• Development of general management capabilities, including immersion in Biogen's commercial philosophies and strategies

• Exposure to various aspects of the biotech industry
Program roles are intentionally challenging and will provide professional stretch and in-depth training with multiple opportunities to learn, take risks and innovate while engaging with customers, patients and other key stakeholders to contribute to the success of Biogen's business from day one.

After the two-year rotational program and proven strong performance, Associates are expected to continue their experience in a full-time leadership role where they will play a critical role in launching the world's first therapy for patients born with this devastating genetic disease. Final placement will be in Biogen's Korea location to focus on Biogen's expanding footprint across Asia-Pacific.

LocationCambridge, MA, US
Job CategoryCommercial Operations
Requisition Number32287BR
QualificationsThe ideal candidate will demonstrate a real curiosity and passion for how commercial organizations and individuals leverage the full range of data-driven approaches to help create outstanding business results for customers. We are also looking for the following characteristics and experience:

• Ability to drive insights from data & analytics

• Self-motivated and results-oriented

• A strong interest in the biotech industry

• Exposure to and experience with strategic consulting skills

• Strong business acumen and demonstrated self-awareness and leadership skills

• Interpersonal competence and exceptional communication skills

• Predisposition towards action and the willingness to do what it takes to "get it done"

• Comfort with risk taking and navigating ambiguity

Final placement at the end of the rotation will be at Biogen's Korea office location. Korean National preferred.
EducationMBA required
About BiogenCorporate Overview

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS). Biogen also manufactures and commercializes biosimilars of advanced biologics. Our global organization of nearly 7,000 employees is committed to a single mission: making a meaningful difference in the lives of patients with few or no treatment options.

One of the pioneers in biotechnology, Biogen was founded in 1978 and today serves patients in nearly 90 countries. Our global headquarters and R&D operations are located in Cambridge, Massachusetts, with an international headquarters in Zug, Switzerland, world-class manufacturing facilities in Research Triangle Park, North Carolina, USA and Hillerod, Denmark, and affiliate locations around the world.

Our Science

We aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry. To us, that means creating novel medicines that benefit individuals and society, and bringing new scientific understanding to diseases for which there are no adequate treatments.

For nearly two decades Biogen has led in the research and development of new therapies to treat MS, including the most prescribed oral treatment in the world. Now our research is driving revolutionary new MS treatments with the goal of reversing or even repairing damage caused by the disease. We are now applying our neurological expertise to solve some of most challenging and complex diseases of the brain, including Alzheimer's disease, Parkinson's disease, and ALS. As we uncover new insights into human biology, Biogen is employing cutting-edge technologies to discover potential treatments for rare and genetic disorders.

Biogen is revolutionizing biologics manufacturing, developing the industry's most advanced plants and processes. This expertise is used to produce both original innovative therapies and biosimilars that expand patient access to lower-cost medicines.

Our Corporate Citizenship

The same intellectual discipline and passion that drives our science is reflected in our corporate citizenship, environmental sustainability, and commitment to diversity and inclusion. As a company, we are focused on improving science education and limiting the impact of our company on the environment. In 2015, we became a carbon neutral company and ranked first place on Newsweek's 2015 Green Rankings, and we are an industry leader on the Dow Jones Sustainability World Index. Biogen was named to Science's list of Top Employers of 2015 and in 2017 received a perfect score of 100 for the fourth consecutive year on the Human Rights Campaign (HRC) Corporate Equality Index, which also named Biogen as one of its Best Places to Work.

All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.

Please be advised that all legitimate correspondence from a Biogen employee will come from "@biogen.com" email accounts.

About Biogen

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company's products address diseases such as multiple sclerosis, lymphoma and rheumatoid arthritis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is used in the treatment of relapsed or refractory low-grade or follicular, CD20-positive, and B-cell, non-Hodgkin's lymphomas (B-cell NHLs). TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. It also has product candidates, such as BG-12 (acquired with the purchase of Fumapharm), ANTI-CD80 antibody/(galiximab), ANTI-CD23 antibody/(lumiliximab), Ocrelizumab/(Humanized ANTI-CD20 Antibody) and Lixivaptan.In January 2007, the Company completed the acquisition of Syntonix Pharmaceuticals, Inc. (Source: 10-K)

This company profile was created by AfterCollege and is about Biogen. This page is not endorsed by or affiliated with Biogen. For questions regarding company profiles, please email: care@aftercollege.com.